PHOENIX, AZ – February 27, 2026 – PRESSADVANTAGE –
Phoenix NP, a women-focused telehealth medical practice based in Phoenix, Arizona, has announced the availability of FDA-approved Wegovy (semaglutide) as part of its medical weight management services for eligible patients across Arizona. The announcement reflects both the continued inclusion of the injectable form of Wegovy and the recent availability of an oral semaglutide option, expanding access for individuals who prefer alternatives to injections. The service is now offered throughout the clinic’s established service areas, including Phoenix, Scottsdale, Tempe, Chandler, Gilbert, Mesa, Tucson, Goodyear, Buckeye, Sedona, and surrounding communities.
Wegovy is an FDA-approved prescription medication indicated for chronic weight management in adults with obesity or overweight who have at least one weight-related medical condition. The medication contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist widely studied for its effects on appetite regulation, metabolic health, and blood sugar control. Until recently, Wegovy has primarily been administered as a once-weekly injection. New developments in oral semaglutide formulations have introduced an additional administration option, broadening how patients may engage with this class of therapy under medical supervision.
Phoenix NP’s inclusion of both injectable and oral semaglutide options reflects an effort to adapt its telehealth services to evolving regulatory approvals and patient preferences. The clinic operates entirely online, providing medical evaluations, follow-up appointments, and ongoing monitoring through scheduled video or phone consultations. This structure allows patients across Arizona to access care without in-person visits, while remaining under the supervision of a licensed Women’s Health Nurse Practitioner.
Semaglutide mimics the action of a naturally occurring hormone involved in appetite signaling and glucose regulation. By slowing gastric emptying and influencing brain regions associated with hunger and satiety, the medication can support reduced caloric intake when used alongside dietary and lifestyle guidance. The oral form of semaglutide is designed to offer similar therapeutic effects while eliminating the need for self-injection, which may be a consideration for some patients evaluating treatment options.
“Expanding access to FDA-Approved Wegovy in both injectable and oral forms allows treatment plans to better align with individual medical needs and preferences,” Founder and provider Jenny Vu said. “The availability of an oral option represents a meaningful development in how semaglutide-based care can be delivered within a medically supervised telehealth setting.”
Eligibility for Wegovy, whether injectable or oral, is determined through a structured clinical intake process. Phoenix NP reviews each patient’s medical history, current health status, and body mass index (BMI) in accordance with FDA guidelines. Wegovy is generally indicated for adults with a BMI of 30 or higher, or 27 or higher in the presence of certain weight-related conditions. Final prescribing decisions are made by the licensed provider following this evaluation, with dosage and formulation selected based on clinical appropriateness.
Phoenix NP emphasizes continuity of care as a core component of its service model. Patients receive ongoing follow-up from the same provider, with monitoring focused on tolerability, progress, and overall health considerations. The clinic’s telehealth platform also includes a secure patient portal that supports appointment scheduling and direct communication related to care coordination.
The addition of oral semaglutide aligns with broader shifts in weight management care, where treatment flexibility and patient adherence are increasingly recognized as important factors. While injectable GLP-1 therapies remain widely used, oral formulations may lower barriers for individuals who are hesitant about injections or who prefer daily oral dosing under medical guidance. Phoenix NP has indicated that both options are discussed during consultations to ensure informed decision-making.
As with other FDA-approved weight management medications, Wegovy is intended to be used as part of a comprehensive medical approach rather than as a standalone solution. Phoenix NP incorporates individualized lifestyle guidance that accounts for metabolic health, daily routines, and long-term sustainability. The clinic’s services are designed specifically for women, with attention given to hormonal changes, reproductive health considerations, and age-related metabolic shifts that may influence weight management.
Phoenix NP serves patients across both urban and regional areas of Arizona, including communities where access to specialized weight management care may be limited. Because services are delivered virtually, patients do not need to travel to a physical office location, provided they reside in the state and meet eligibility requirements.
The clinic operates on a direct-pay model for provider services, separate from medication costs. Prescriptions for FDA-approved Wegovy are sent to authorized partner pharmacies that dispense manufacturer-produced medications. This approach reflects Phoenix NP’s stated commitment to providing regulated therapies rather than compounded alternatives, in line with current FDA guidance.
The announcement of expanded Wegovy availability follows ongoing changes within the medical weight management landscape, including increased demand for GLP-1 receptor agonist therapies and evolving options for medication delivery. Phoenix NP’s integration of both injectable and oral semaglutide options is intended to keep its telehealth offerings aligned with current clinical developments.
Phoenix NP was established to address access challenges in women-centered medical weight management, particularly for patients balancing work and family responsibilities with limited appointment availability. The clinic offers evening and weekend consultation times to accommodate varied schedules and emphasizes consistent provider involvement throughout care.
Additional information about FDA-Approved Wegovy (semaglutide), including injectable and oral options, eligibility criteria, and Phoenix NP’s telehealth services, is available through the clinic’s official website.
###
For more information about Phoenix NP, contact the company here:
Phoenix NP
Michael Lim
(480) 382-0176
info@phoenixnptelehealth.com
1801 E Camelback Rd 102 1278, Phoenix, AZ 85016
